Validation and Implementation of 3T MRI Research Protocols

NCT04866940 | Recruiting

• 1 other identifier: C20-28
• Study Type: interventional
• Target: 230
• Locations: 1 country
• Sites: 1

Brief Summary

The Philips 3T imager installed on the Pavillon Baudot site is an imager dedicated solely to research. It is not located in hospital premises but in INSERM premises for which an authorization for biomedical research has been granted. This equipment is part of the Technical Platform of the UMR 1214 ToNIC whose main objective is the study of the human brain and the main pathologies that affect it. MRI is an evolving technique, which is used in many research projects. Our technical platform must follow these developments and remain at the cutting edge. One of the essential services of our technical platform is to help set up research protocols and validate acquisition sequences. This development activity is therefore located upstream of research projects involving clinical or fundamental applications. The fact that we can provide our users with a regulatory framework to carry out these development tests for their Research Involving Human Subjects project is a necessity for our research support activity. This study aims to provide a generic framework to test the feasibility of MRI sequences requested within the framework of protocols, but also to optimize MRI acquisition sequences already in place, to improve image quality and reduce artifacts that can degrade the quality of the images obtained. In France, there are just over 35 centers with MRI dedicated to research and therefore with a validation protocol allowing them to validate their sequences.

Conditions

Magnetic Resonance Imaging

Outcome Measures

Primary Outcomes (1)

• in general

  optimization of parameters acquisition in order to suppress artefact

  at the end of studies ((i.e. one hour and a half including the installation and the delays between the sequences). Each sequence lasts between 5 and 20 minutes.

Study Arms (1)

Sequence validation

EXPERIMENTAL

This research aims to provide a generic framework to test the feasibility of MRI sequences requested as part of protocols, but also to optimize MRI acquisition sequences already in place, to improve image quality and reduce artifacts that can degrade the quality of images obtained.

Other: Sequences test

Interventions

Sequences test OTHER

the realization of preliminary acquisitions to validate the feasibility of clinical or cognitive research protocols

Sequence validation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female, 18 years of age or older
• Ability to cooperate and remain motionless for up to 1 hour (and lying down for 1.5 hours)
• Ability to understand the instructions given
• Subject who has given written and informed consent prior to any examination required by the research)
• Subject affiliated to a social security system or benefiting from an equivalent system

You may not qualify if:

• Persons deprived of liberty by judicial or administrative decision
• Psychiatric disorders, disorders of cognitive functions, not allowing the realization of the MRI
• Protected adults (subject to a measure of legal protection) or unable to express their consent
• Subject with Contraindications to MRI

Sponsors & Collaborators

• Institut National de la Santé Et de la Recherche Médicale, France: lead

Study Sites (1)

UMR 1214 ToNIC INSERM

Toulouse, 31000, France

RECRUITING

Study Officials

• Pierre PAYOUX, Pr

  Inserm: UMR 1214 ToNIC

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Nathalie VAYSSIERE, PHD

CONTACT

+33562746132; nathalie.vayssiere@cnrs.fr

DAGNAC, PHD

CONTACT

+33562746122; helene.gros@inserm.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 7, 2021
• First Posted: April 30, 2021
• Study Start: May 12, 2021
• Primary Completion (Estimated): May 12, 2027
• Study Completion (Estimated): May 12, 2027
• Last Updated: February 18, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)